 - Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide GIP - - First planned indication is Prader-Willi Syndrome- - IND-enabling studies ongoing with first-in-human studies anticipated in 2023 - - Transaction does not impact corporate guidance and company remains fully financed into 2023 with co-lead programs in short bowel syndrome Phase 2 and in celiac disease Phase 3 - RALEIGH, NC ACCESSWIRE July 19, 2021 9 Meters Biopharma, Inc. NASDAQ:NMTR, a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company has acquired global development rights to a proprietary and highly specific humanized monoclonal antibody mAb, LOB-0136 now known as NM-136 that targets glucose-dependent insulinotropic polypeptide GIP, in addition to related intellectual property from Lobesity LLC, a privately-held biotechnology company focused on breakthrough research and development for metabolic diseases and related disorders. GIP is a hormone found in the upper small intestine that is released into the blood after food is ingested. 